rosiglitazona

Rosiglitazona / Rosiglitazone

Portal Fármacos|| Portal Diabetes || Tiazolidinedionas

COMUNICACIÓN SOBRE RIESGOS DE MEDICAMENTOS PARA PROFESIONALES SANITARIOS Ref: 2008/02 28 de enero de 2008 NOTA INFORMATIVA ROSIGLITAZONA Y RIESGO CARDIOVASCULAR: NUEVAS CONTRAINDICACIONES Y RESTRICCIONES DE USO

PIOGLITAZONA Y ROSIGLITAZONA: CONCLUSIONES DE LA EVALUACIÓN DEL BALANCE BENEFICIO-RIESGO EN EUROPA, COMUNICACIÓN SOBRE RIESGOS DE MEDICAMENTOS PARA PROFESIONALES SANITARIOS, Agemed

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes. Steven E. Nissen, M.D., and Kathy Wolski, M.P.H. Published at www.nejm.org May 21, 2007 (10.1056/NEJMoa072761

Realizado con los datos de ensayos clínicos publicados, así como en la base de datos de la FDA y en el registro de ensayos clínicos del laboratorio fabricante los resultados muestran que la rosiglitazona se asocio con un aumento del riesgo de infarto de miocardio y con un aumento del riesgo de muerte por causa cardiovasculares, bordeando la significación estadística. Aparte de esta limitación en la magnitud del efecto también el estudio se vio limitado por la falta de acceso a las fuentes originales de los datos lo que podría haber mejorado el análisis del tiempo hasta el evento. Los potenciales efectos adversos graves asociados con el uso de rosiglitasona (este y otros) en la diabetes tipo 2 hacen que estos medicamentos deban ser considerados con mucha más precaución que la que inicialmente recomendaban guías y expertos

 

Ficha Técnica de la EMEA . Comercializado como Avandia y como Avandamet en combinación con metformina

 

Bibliografía en PUBMED en Core Clinical Journals



CITED2 is a novel direct effector of peroxisome proliferator-activated receptor gamma in suppressing hepatocellular carcinoma cell growth.
Cancer. 2013 Mar 15; 119(6): 1217-26. Cheung, Kin-Fai; Zhao, Junhong; Hao, Ying; Li, Xiaoxing; Lowe, Anson W; Cheng, Alfred S L; Sung, Joseph J Y; Yu, Jun;

A clinical trial to maintain glycemic control in youth with type 2 diabetes.
The New England journal of medicine. 2012 Jun 14; 366(24): 2247-56. Zeitler, Phil; Hirst, Kathryn; Pyle, Laura; Linder, Barbara; Copeland, Kenneth; Arslanian, Silva; Cuttler, Leona; Nathan, David M; Tollefsen, Sherida; Wilfley, Denise; Kaufman, Francine;

Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis.
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 2012 Sep 4; 184(12): E675-83. Colmers, Isabelle N; Bowker, Samantha L; Majumdar, Sumit R; Johnson, Jeffrey A;

In vivo JNK activation in pancreatic beta-cells leads to glucose intolerance caused by insulin resistance in pancreas.
Diabetes. 2013 Jul; 62(7): 2308-17. Lanuza-Masdeu, Jordi; Arevalo, M Isabel; Vila, Cristina; Barbera, Albert; Gomis, Ramon; Caelles, Carme;

SUMO-1 regulates body weight and adipogenesis via PPARgamma in male and female mice.
Endocrinology. 2013 Feb; 154(2): 698-708. Mikkonen, Laura; Hirvonen, Johanna; Janne, Olli A;

Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes.
Archives of internal medicine. 2012 Jul 9; 172(13): 1005-11. Idris, Iskandar; Warren, Graham; Donnelly, Richard;

Results of a reevaluation of cardiovascular outcomes in the RECORD trial.
American heart journal. 2013 Aug; 166(2): 240-249.e1. Mahaffey, Kenneth W; Hafley, Gail; Dickerson, Sheila; Burns, Shana; Tourt-Uhlig, Sandra; White, Jennifer; Newby, L Kristin; Komajda, Michel; McMurray, John; Bigelow, Robert; Home, Philip D; Lopes, Renato D;

Metformin prevents the development of chronic heart failure in the SHHF rat model.
Diabetes. 2012 Apr; 61(4): 944-53. Cittadini, Antonio; Napoli, Raffaele; Monti, Maria Gaia; Rea, Domenica; Longobardi, Salvatore; Netti, Paolo Antonio; Walser, Marion; Sama, Mariateresa; Aimaretti, Gianluca; Isgaard, Jorgen; Sacca, Luigi;

Rosiglitazone promotes PPARgamma-dependent and -independent alterations in gene expression in mouse islets.
Endocrinology. 2012 Oct; 153(10): 4593-9. Welters, Hannah J; El Ouaamari, Abdelfattah; Kawamori, Dan; Meyer, John; Hu, Jiang; Smith, David M; Kulkarni, Rohit N;

Developmental programming: prenatal and postnatal contribution of androgens and insulin in the reprogramming of estradiol positive feedback disruptions in prenatal testosterone-treated sheep.
Endocrinology. 2012 Jun; 153(6): 2813-22. Abi Salloum, Bachir; Herkimer, Carol; Lee, James S; Veiga-Lopez, Almudena; Padmanabhan, Vasantha;

High glucose represses beta-klotho expression and impairs fibroblast growth factor 21 action in mouse pancreatic islets: involvement of peroxisome proliferator-activated receptor gamma signaling.
Diabetes. 2013 Nov; 62(11): 3751-9. So, Wing Yan; Cheng, Qianni; Chen, Lihua; Evans-Molina, Carmella; Xu, Aimin; Lam, Karen S L; Leung, Po Sing;

Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: study design and conduct.
American heart journal. 2013 Aug; 166(2): 208-216.e28. Lopes, Renato D; Dickerson, Sheila; Hafley, Gail; Burns, Shana; Tourt-Uhlig, Sandra; White, Jennifer; Newby, L Kristin; Komajda, Michel; McMurray, John; Bigelow, Robert; Home, Philip D; Mahaffey, Kenneth W;

Rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.
Circulation. 2013 Aug 20; 128(8): 785-94. Bach, Richard G; Brooks, Maria Mori; Lombardero, Manuel; Genuth, Saul; Donner, Thomas W; Garber, Alan; Kennedy, Laurence; Monrad, E Scott; Pop-Busui, Rodica; Kelsey, Sheryl F; Frye, Robert L;

Discordant effects of rosiglitazone on novel inflammatory biomarkers.
American heart journal. 2013 Apr; 165(4): 609-14. Gada, Elan; Owens, Andrew W; Gore, M Odette; See, Raphael; Abdullah, Shuaib M; Ayers, Colby R; Rohatgi, Anand; Khera, Amit; de Lemos, James A; McGuire, Darren K;

Weight loss improves the adipogenic capacity of human preadipocytes and modulates their secretory profile.
Diabetes. 2013 Jun; 62(6): 1990-5. Rossmeislova, Lenka; Malisova, Lucia; Kracmerova, Jana; Tencerova, Michaela; Kovacova, Zuzana; Koc, Michal; Siklova-Vitkova, Michaela; Viquerie, Nathalie; Langin, Dominique; Stich, Vladimir;

Role of peroxisome proliferator activated receptor-gamma in bacillus Calmette-Guerin bladder cancer therapy.
The Journal of urology. 2012 Dec; 188(6): 2384-90. Langle, Yanina; Lodillinsky, Catalina; Belgorosky, Denise; Sandes, Eduardo Omar; Eijan, Ana Maria;

Rosiglitazone reverses mitomycin C resistance in human gastric cancer cells.
The American journal of the medical sciences. 2012 May; 343(5): 382-7. Zhang, Li; Hu, Jian-Feng; Li, Guo-Qing; Xiao, Xiang; Su, Qi;

Quantitative whole-body MRI in familial partial lipodystrophy type 2: changes in adipose tissue distribution coincide with biochemical improvement.
AJR. American journal of roentgenology. 2012 Nov; 199(5): W602-6. McLaughlin, Patrick D; Ryan, James; Hodnett, Phillip A; O'Halloran, Domhnall; Maher, Michael M;

Metabolic stress-induced inflammation plays a major role in the development of osteoarthritis in mice.
Arthritis and rheumatism. 2012 Apr; 64(4): 1172-81. Gierman, L M; van der Ham, F; Koudijs, A; Wielinga, P Y; Kleemann, R; Kooistra, T; Stoop, R; Kloppenburg, M; van Osch, G J V M; Stojanovic-Susulic, V; Huizinga, T W; Zuurmond, A-M;

Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus.
The Journal of clinical endocrinology and metabolism. 2013 Apr; 98(4): 1519-28. Bilezikian, John P; Josse, Robert G; Eastell, Richard; Lewiecki, E Michael; Miller, Colin G; Wooddell, Margaret; Northcutt, Allison R; Kravitz, Barbara G; Paul, Gitanjali; Cobitz, Alexander R; Nino, Antonio J; Fitzpatrick, Lorraine A;


Subir